Why the study?
The cost-effectiveness of newer DES such as biodegradable-polymer or polymer-free stents with shorter DAPT duration was unknown.
Is short-duration DAPT with newer DES cost-effective compared to longer-duration DAPT with second-generation DES in patients with stable coronary disease?
Is short-duration DAPT with newer DES cost-effective compared to longer-duration DAPT with second-generation DES in patients with stable coronary disease?
Newer DES platforms with 3 months of DAPT are likely cost-effective for patients at elevated bleeding risk, but standard second-generation DES with 6 months of DAPT remains preferred for those with average bleeding risk.
Answers are grounded in this paper and cite their sources.
May support shorter DAPT with newer DES in high-bleeding-risk patients; leaves open need for randomized confirmation.
BACKGROUND: The cost-effectiveness of newer drug-eluting stents (DES) such as biodegradable-polymer or polymer-free stents with shorter dual antiplatelet therapy (DAPT) duration is unknown. We evaluated the cost-effectiveness of treatment with newer DES that may allow for shorter DAPT duration. PATIENTS AND METHODS: We performed a cost-effectiveness analysis of treatment with newer DES platforms followed by 1 or 3 months of DAPT compared with standard second-generation DES followed by 6 or 12 months of DAPT in patients with stable coronary disease. A Markov model simulated distinct health states over a lifetime. Probabilistic sensitivity analysis and one-way sensitivity analyses were performed. A high-risk bleeding scenario was also evaluated. RESULTS: Among patients with typical bleeding risk, second-generation DES and 6 months of DAPT was less expensive and resulted in marginally higher quality-adjusted life years compared with other strategies. A newer DES platform and 3 months of DAPT was preferred when the risk of fatal bleeding was two times greater than baseline, or when bleeding increased long-term mortality by a factor of 1.5. In a probabilistic sensitivity analysis, second-generation DES and 6 months of DAPT was preferred in 58% of iterations, whereas in a high-risk bleeding patient scenario, a newer DES and 3 months of DAPT was preferred in 52% of iterations. CONCLUSION: A DES that allows 3 months of DAPT without increasing stent-related events is likely to be cost-effective among patients at elevated risk of bleeding, but not in patients with average bleeding risk.
No takes yet. Share an insight, caveat, or question.
Galper et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: